Anti-Cancer Agents Synthesized Based on Miliusane Compounds
- 总结
- The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to new anticancer agents based on the miliusane compounds. The present invention also includes its preparation and application method for treating cancer
- 技术优势
- Miliusanes compounds with an improved anticancer activity and low in toxicity
- 技术应用
- For use in the treatment, prevention or delay of progression of a cancer, particularly colon cancer, breast cancer, prostate cancer, lung cancer, melanoma, leukemia, brain cancer, renal cancer, ovarian cancer, and oral epidermoid cancer.
- 详细技术说明
- The present invention relates to anticancer agents which are synthesized based on miliusane. More particularly, the agents are derivatives of the core structures of miliusanes.
- 附加资料
- Patent Number: US9211333B2
Application Number: US13831997A
Inventor: Zhang, Hongjie
Priority Date: 5 Jun 2012
Priority Number: US9211333B2
Application Date: 15 Mar 2013
Publication Date: 15 Dec 2015
IPC Current: A61K004506 | A61K0031343 | A61K00314025 | C07D030794 | C07D040512 | C07D040706 | C07D040912
Assignee Applicant: Hong Kong Baptist University
Title: Anti-cancer agents synthesized based on miliusane compounds
Usefulness: Anti-cancer agents synthesized based on miliusane compounds
Summary: (I) are useful for treating, preventing or delaying progression of a cancer in a subject (human), where the cancer is colon cancer, breast cancer, prostate cancer, lung cancer, melanoma, leukemia, brain cancer, renal cancer, ovarian cancer, and oral epidermoid cancer (all claimed). Test details are described but no results for the compounds of the claims are given.
Novelty: New substituted miliusane derivatives useful for treating cancer e.g. colon cancer, breast cancer, lung cancer, melanoma, leukemia, brain cancer, renal cancer and ovarian cancer in human
- 主要类别
- 诊断/治疗
- 细分类别
- 癌症/肿瘤
- 申请日期
- 2013.03.15
- 申请号码
- US 13/831,997
- 其他
- Filed
- ID号码
- A61/ZH/Mili/US01
- 国家/地区
- 香港
欲了解更多信息,请点击 这里